Pharmax: Affordable high-quality medicines

Top Stories

Madhukar Tanna, Chief Executive Officer, Pharmax
Madhukar Tanna, Chief Executive Officer, Pharmax

The Dubai-based brand's focus is on saving lives

  • Follow us on
  • google-news
  • whatsapp
  • telegram

Published: Thu 9 Jul 2020, 8:45 AM

Last updated: Sun 12 Jul 2020, 10:50 AM

As the first UAE-based pharmaceutical manufacturing company in Dubai Science Park, Pharmax is supporting the UAE healthcare sector with high-quality, affordable medicines. Its focus is commercialising branded generic medication for chronic medical conditions across a broad range of therapeutic segments. In the last nine months, Pharmax has successfully launched fifteen new products with more in the pipeline. These include pharmaceuticals for pain and inflammation; urological, psychiatric and neurological disorders; cardiovascular disease; diabetes; allergies and asthma; and gastroenterology. And it will soon be introducing specialised products for women's health.

With pharmaceutical sales in the UAE set to reach US$3.8 billion by 2021, the brand is a growing business ready to meet the region's dynamic requirements. Which is why they are currently looking at expansion to Saudi Arabia, Yemen, Iraq and several other MENA markets.
Madhukar Tanna, CEO at Pharmax said: "At Pharmax, quality is a corporate culture built into every level of our organisation. We take our responsibility seriously and apply the same standards to our partner companies as to our own employees. We invest significant time and resources in training, to ensure that the highest quality is maintained right across our value chain. Our ultimate goal is to deliver products that will improve the lives of patients.

"Our production capacity has been mapped to cater to the demands of our own branded products and provide additional contract manufacturing services. Aurobindo Labs and Cipla from India, and MS Pharma from Jordan, are our current partners and more will be added soon."
Today, Pharmax is able to produce over 300 million tablets and capsules in its Dubai facility, backed by the latest Quality Management Systems certification, and FDA 21 CFR Part 11 software. In 2019, the company also received European Union Good Manufacturing Practice certification, which opens many opportunities in new markets, not only in the region but also in the EU.

The UAE Ministry of Health and Prevention (MoHAP) also recently approved Pharmax as the UAE's first laboratory for batch release of respiratory products, such as inhalers and nasal sprays. This will add significant value to its existing product portfolio.

Pharmax has also invested in the capability to release injectable formulations, to meet the demands for these types of medicine in the UAE. With the current Covid-19 health situation, the demand for generic medicine is likely to increase significantly and turning to local production will be key to fulfilling demand.

"As MoHAP celebrates 50 years, it has created one of the best healthcare standards in the region. The advent of universal health insurance has created significant change when it comes to accessing affordable, high-quality products. Private and public hospitals and community healthcare providers now depend on our products to ensure their patients receive their treatments on time, and to maintain their overall cost structure. As we look at the future, our mission at Pharmax will continue to be to support MoHAP, by producing affordable products at the highest quality standards, to help match the region's rising demands," Tanna stated.



More news from